Survival beneft of cancer‑directed surgery and the role of adjuvant therapy in malignant major salivary gland cancers: a propensity score matched retrospective analysis
Date
2025-01-09
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
W.B. Saundersw
Series Info
Oral and Maxillofacial Surgery ; (2025) 29:27
Scientific Journal Rankings
Abstract
Background The primary objective of this study was to assess the beneft of cancer-directed surgery (CDS) on both overall
survival (OS) and cancer-specifc survival (CSS) of patients with malignant major salivary gland cancers (MMSGCs). The
secondary objective was to explore the benefts of adjuvant therapy on the survival outcomes of these patients.
Methods Patients diagnosed with MMSGC were extracted from the SEER database and subsequently categorized into two
cohorts: CDS and non-CDS. Propensity score matching (PSM) was used to mitigate confounding variables. The survival
beneft associated with CDS was evaluated using Kaplan–Meier analysis, log-rank tests, and Cox proportional hazard models.
Furthermore, the impact of adjuvant radiotherapy and chemotherapy was explored within the CDS subgroup.
Results A total of 7,029 patients with MMSGC were included. PSM was performed and resulted in a matched cohort between
both groups, including 595 patients in each group. Multivariable Cox proportional hazard indicated that patients who received
CDS had better OS (HR: 0.45, 95% CI [0.39 to 0.52], P<0.001) and CSS (HR: 0.46, 95% CI [0.40 to 0.52], P<0.001).
The 5- and 10-year OS for the CDS group was 42% (95% CI, 38 −46%), and 25% (95% CI, 21 −29%) consecutively, while
the 5- and 10-year OS for the non-CDS group was 20% (95% CI, 17 −24%), and 12% (95% CI, 9.7 −16%) consecutively.
Moreover, patients with younger age, localized tumors, and lower TNM stage could beneft more from CDS. Radiotherapy
as adjuvant therapy was found to be benefcial (HR: 0.69, 95% CI [0.55–0.85], p<0.001), while chemotherapy could not
signifcantly beneft these patients.
Conclusion CDS improved the OS and CSS survival in MMSGC patients. Specifc patient subgroups seemed to have a
superior beneft from CDS. Adjuvant radiotherapy could help enhance the survival outcomes of these patients while chemotherapy could not.
Description
Q1
Keywords
Salivary gland cancer · Cancer-directed surgery · Adjuvant therapy · Propensity score matching
Citation
Elkoumi, A., Elkoumi, O., Elkasaby, M. H., Khitiy, H., Elbairy, M. K., Tawfik, A., Habib, O. K., & Shaalan, A. (2025). Survival benefit of cancer-directed surgery and the role of adjuvant therapy in malignant major salivary gland cancers: a propensity score matched retrospective analysis. Oral and Maxillofacial Surgery, 29(1). https://doi.org/10.1007/s10006-024-01316-0